Author: therawinformant

from Yahoo Finance https://ift.tt/2Ah6oz2

from Yahoo Finance https://ift.tt/2CTds5T

ROBO Global Senior Research Analyst Nina Deka joins Yahoo Finance’s On The Move panel to address the dangers of chasing coronavirus vaccine stocks.

from Yahoo Finance https://ift.tt/3eYILu4

Gold prices could stay on a hot streak. Here's why this gold industry insider thinks so.

from Yahoo Finance https://ift.tt/3gcczDR

Inovio Pharmaceuticals (INO) on Tuesday announced “positive” interim clinical data results of INO-4800, its experimental vaccine candidate against the novel coronavirus.Shares, however dropped 12% to $27.74 in midday U.S. trading, suggesting investors were taking the results with a grain of salt. The value of the stock has this year already ballooned 740%.Inovio said that the early-stage clinical data demonstrated that INO-4800 resulted in immune responses and was generally safe and well-tolerated in all participants in the first two Phase 1 trial cohorts. In addition, the biotech company announced that INO-4800 has been selected to participate in a non-human primate (NHP) challenge study as part of the U.S. government's Operation Warp Speed, a national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021."We are very encouraged by the positive interim safety and preliminary cellular and humoral immune response results to date as well as the inclusion of INO-4800 in Operation Warp Speed,” Inovio President and CEO Joseph Kim said. “We are also pleased that INO-4800 vaccination abrogated viral replication in the lungs of mice challenged with SARS-CoV-2.”Furthermore, Inovio added that it has expanded its Phase 1 trial to add older participants in additional cohorts and plans to initiate a Phase 2/3 efficacy trial this summer upon regulatory concurrence.The Phase 1 clinical trial of INO-4800 initially enrolled 40 healthy adult volunteers in the age of 18 to 50 years at two U.S. sites. About 94% of Phase 1 trial participants demonstrated overall immune responses at week 6 after two doses of INO-4800 in trial with the 40 healthy volunteers in preliminary analyses.INO-4800 targets the major antigen Spike protein of SARS-CoV-2 virus, which causes Covid-19 disease.Following Inovio’s stellar rally this year, five-star analyst Ram Selvaraju at H.C. Wainwright on Monday downgraded the stock to Hold from Buy and withdrew his price target."We believe the risk/reward ratio for Inovio has increased significantly as many open questions remain, including the strength and duration of neutralizing antibodies and T cell responses that may be generated in human trials and the effective protection the vaccine may demonstrate in animal challenge studies," Selvaraju said in a note to investors.The skepticism stems from the fact that there is no approved human vaccine for any type of coronavirus and that no DNA vaccines have been approved yet for human use, he added.The Street has a cautiously optimistic outlook on Inovio, with a Moderate Buy analyst consensus based on 3 Buy ratings versus 5 Hold ratings. As the share price spiked so fast this year, the $27.80 average analyst price target now indicates shares are more than fully priced. (See Inovio stock analysis on TipRanks).Related News: Gilead Sets Pricing for Covid-19 Treatment Remdesivir at $2,340 Per Patient    AstraZeneca Strikes $127 Million Deal With Brazil For Covid-19 Vaccine Vaxart Explodes 96%- And Rallies After-Hours- On Covid-19 Deal More recent articles from Smarter Analyst: * Wells Fargo Plans To Cut Its Dividend In Q3; Top Analyst Lowers Price Target * Lululemon To Acquire At-Home Fitness Mirror For $500M * Tesla’s Elon Musk Asks Workers To Help Company Break Even in Second Quarter * Norwegian Air Cancels 97 Boeing Aircraft, Seeks Compensation

from Yahoo Finance https://ift.tt/2ZoIhXJ

Tesla Inc.’s (TSLA) CEO billionaire Elon Musk is reportedly asking employees to work hard to allow the electric car maker to break even in the second quarter.According to an internal email seen by Reuters, Musk is encouraging employees to quickly build and deliver vehicles at the end of the quarter to meet specific targets after production was disrupted due to restrictions tied to the coronavirus pandemic.“Breaking even is looking super tight,” Musk said in the Monday email. “Really makes a difference for every car you build and deliver. Please go all out to ensure victory!”Shares rose 5.2% to 1,009.35 at the close on Monday. The plea comes as the automaker is this week expected to release its second-quarter delivery numbers report. Analysts on average expect the company to deliver about 74,000 vehicles in the months from April to June.Ahead of the delivery report, JMP Securities analyst Joseph Osha today raised the stock’s price target to $1,050 (4% upside potential) from $1,001 and maintained a Buy rating, saying that the consensus for Q2 unit deliveries looks "reasonable" as the strength of the China market appears to be sufficient to offset a "disastrous" quarter in the U.S. and Europe.Osha estimates that Tesla should be able to grow its delivery volumes by 14% in 2020.The company’s California vehicle factory was closed for more than six weeks with production disrupted from the end of March to early May due to local lockdown orders aimed at slowing the spread of the coronavirus pandemic.In April, Tesla surprised investors when it said production and delivery of its new sport utility vehicle, Model Y, was significantly ahead of schedule despite the virus outbreak. The company delivered 88,400 vehicles in the first quarter.Despite the disruptions, shares have this year seen a great run and have now more than doubled in value. So it is not surprising that the $733.43 average price target now implies 27% downside potential for the shares in the coming 12 months. (See Tesla’s stock analysis on TipRanks).Overall, the stock has a Hold analyst consensus with 10 Sell ratings and 10 Hold ratings versus 7 Buy ratings.Related News: Nvidia, Mercedes Partner On Autonomous Vehicle Venture; A ‘Match Made In Auto Heaven’ Says Oppenheimer Tesla Said To Have Won Chinese Nod To Build Model 3 With LFP Batteries Can Tesla Provide the Million Mile EV Battery? Top Analyst Weighs In More recent articles from Smarter Analyst: * Inovio Presents ‘Positive’ Early Data For Covid-19 Vaccine Candidate; Shares Plunge 12% * Wells Fargo Plans To Cut Its Dividend In Q3; Top Analyst Lowers Price Target * Lululemon To Acquire At-Home Fitness Mirror For $500M * Norwegian Air Cancels 97 Boeing Aircraft, Seeks Compensation

from Yahoo Finance https://ift.tt/2Ah5v9P

Bill Brown, L3Harris CEO, joins The First Trade to discuss his company’s $1 billion contract with the U.S. government and the commercial airline industry as national debt continues to rise.

from Yahoo Finance https://ift.tt/31vfX8P

If you are looking for the best ideas for your portfolio you may want to consider some of Wedgewood Partners top stock picks. Wedgewood Partners, an investment management firm, is bullish on Alphabet Inc. (NASDAQ:GOOG) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed its investment […]

from Yahoo Finance https://ift.tt/3ePudgr

NPC international is expected to file for bankruptcy. Yahoo Finance’s Brian Sozzi, Jared Blikre, and Heidi Chung discuss.

from Yahoo Finance https://ift.tt/3i9PO5g

from Yahoo Finance https://ift.tt/2BX0rHV